本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海睿昂基因科技股份有限公司董事会 2026 年 1 月 24 日 前期，公司实际控制人熊慧女士、熊钧先生因涉嫌诈骗罪已被批捕。近日， 公司收到实际控制人熊慧女士、熊钧先生家属的通知，实际控制人熊慧女士、熊 钧先生因涉嫌诈骗罪已被检察机关向法院提起诉讼。 熊慧女士、熊钧先生目前未在公司担任董事或高级管理人员职务，上述事项 不会对公司日常经营活动产生重大不利影响。公司具备完善的法人治理结构与内 部控制体系，各项经营管理工作均有明确的流程保障，公司日常经营管理由高管 团队负责，董事及高级管理人员目前均正常履职。目前，公司业务正常开展，经 营活动正常进行。 公司将持续关注上述事项的进展情况，并严格按照有关法律、法规的规定和 要求，及时履行信息披露义务。公司指定信息披露媒体为《上海证券报》《中国 证券报》《证券时报》《证券日报》及上海证券交易所网站（www.sse.com.cn）， 公司发布的信息均以在上述指定媒体披露的信息为准，敬请广大投资者理性投资， 并注意投资风险。 特此公告。 ...

证券代码：688217 证券简称：睿昂基因 公告编号：2026-001 上海睿昂基因科技股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 二、上年同期业绩情况 （一）2024 年度，公司实现营业收入为 24,230.62 万元；实现利润总额为 -2,847.45 万元；实现归属于母公司所有者的净利润为-1,576.45 万元；归属于母 公司所有者的扣除非经常性损益的净利润为-1,924.76 万元。 （二）每股收益：-0.28 元/股。 三、本期业绩变化的主要原因 报告期内，公司实现归属于母公司所有者的净利润和归属于母公司所有者的 扣除非经常性损益的净利润同比出现较大幅度的下滑，主要有以下四个方面的原 因： （二）业绩预告情况 1、经财务部门初步测算，上海睿昂基因科技股份有限公司（以下简称"公 司"）预计 2025 年年度实现营业收入 17,000.00 万元至 17,600. ...

格隆汇1月23日丨睿昂基因(688217.SH)公布，公司预计2025年年度实现归属于母公司所有者的净利润将 出现亏损，实现归属于母公司所有者的净利润为-3,990.69万元到-5,986.03万元。公司预计2025年年度实 现归属于母公司所有者的扣除非经常性损益的净利润为-4,990.69万元至-6,986.03万元。 ...

南财智讯1月23日电，睿昂基因发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-3990.69万元至-5986.03万元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润 为-4990.69万元至-6986.03万元。报告期内，公司实现归属于母公司所有者的净利润和归属于母公司所 有者的扣除非经常性损益的净利润同比出现较大幅度的下滑，主要有以下四个方面的原因：1、受体外 诊断行业竞争加剧以及本公司特殊事件的影响，2025年营业收入较上年下降约6,630.62万元至7,230.62万 元，同比减少27.36%至29.84%，营业收入下降导致毛利金额下降；2、报告期内，受医疗行业环境影 响，下游客户回款变慢，公司根据坏账政策增加计提应收账款信用减值损失；3、报告期内，（1）公司 分子诊断试剂研发中心及产业化建设项目暂停，且暂无续建计划，公司判断其存在减值迹象，对其计提 减值损失；（2）由于外部市场环境发生变化，子公司上海源奇生物本期业绩进一步下滑，公司结合未 来经营情况的判断，对该子公司的商誉计提减值损失；（3）由于外部市场环境发生变化，子公司武汉 百泰本期业绩进一步下滑，公司判断其 ...

睿昂基因公告，预计2025年年度实现归属于母公司所有者的净利润将出现亏损，实现归属于母公司所有 者的净利润为-3990.69万元到-5986.03万元。报告期内，受医疗行业环境影响，下游客户回款变慢，公 司根据坏账政策增加计提应收账款信用减值损失。 ...

Market Overview - The medical device sector experienced a decline of 0.74% on December 29, with Huakang Clean leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] Top Performers - Meihao Medical (301363) saw a closing price of 25.04, with an increase of 8.30% and a trading volume of 197,100 shares, totaling a transaction value of 482 million yuan [1] - Mailande (688273) closed at 41.73, up 8.22%, with a trading volume of 55,200 shares and a transaction value of 227 million yuan [1] - Kangzhong Medical (688607) closed at 45.80, up 7.23%, with a trading volume of 40,200 shares and a transaction value of 180 million yuan [1] Underperformers - Huakang Clean (301235) closed at 39.21, down 8.54%, with a trading volume of 123,300 shares and a transaction value of 488 million yuan [2] - C Jianxin (688805) closed at 47.16, down 7.26%, with a trading volume of 89,000 shares and a transaction value of 426 million yuan [2] - Furuim Medical (300049) closed at 71.93, down 4.20%, with a trading volume of 66,800 shares and a transaction value of 485 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 565 million yuan from institutional investors, while retail investors experienced a net inflow of 328 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Meihao Medical (301363) had a net outflow of 54.30 million yuan from institutional investors, with retail investors also showing a net outflow of 0.76 million yuan [3] - Jigaofazhan (600807) experienced a net inflow of 44.75 million yuan from institutional investors, while retail investors had a net outflow of 61.29 million yuan [3] - Kangzhong Medical (688626) saw a net inflow of 44.26 million yuan from institutional investors, with retail investors showing a slight net outflow [3]

Group 1 - The core point of the article highlights that Ruiang Gene's stock experienced a decline of 1.36%, closing at 26.12 yuan, with a significant block trade occurring [1] - A total of 400,000 shares were traded in the block transaction, amounting to 9.408 million yuan, with a transaction price of 23.52 yuan, reflecting a premium rate of -9.95% [1] - The buyer was Guoyuan Securities Co., Ltd., while the seller was Donghai Securities Co., Ltd., indicating active trading interest from institutional players [1] Group 2 - Over the past three months, Ruiang Gene has recorded only one block trade, with a total transaction value of 9.408 million yuan [1] - In the last five trading days, the stock has seen a cumulative decline of 1.99%, with a net outflow of 2.3449 million yuan from major funds [1]

Group 1 - The core transaction involved 400,000 shares of Ruian Gene, with a total transaction value of 9.408 million yuan, representing 35.93% of the total trading volume on that day [1] - The transaction price was 23.52 yuan per share, which is a discount of 9.95% compared to the market closing price of 26.12 yuan [1] Group 2 - The transaction occurred on December 26, with the stock code 688217 for Ruian Gene [2] - The buying brokerage involved in the transaction was "零部長薪盤當落燈," while the selling brokerage was "藝禮攝發驚鬼露" [2]

Core Insights - The precision medicine sector experienced a 1.92% increase on November 24, with Guomai Technology leading the gains [1] - The Shanghai Composite Index closed at 3836.77, up 0.05%, while the Shenzhen Component Index closed at 12585.08, up 0.37% [1] Stock Performance - Guomai Technology (002093) closed at 12.19, up 10.02% with a trading volume of 446,600 shares and a transaction value of 536 million [1] - Zhongyuan Xiehe (600645) also rose by 10.02% to 28.23, with a trading volume of 169,100 shares and a transaction value of 468 million [1] - Other notable performers include: - Toukeng Life (300642) at 19.51, up 3.34% [1] - Beirui Gene (000710) at 11.97, up 3.28% [1] - Yangjin Medical (300030) at 7.90, up 3.27% [1] Capital Flow - The precision medicine sector saw a net inflow of 526 million from institutional investors, while retail investors experienced a net outflow of 143 million [2] - The main capital inflow and outflow for key stocks include: - WuXi AppTec (603259) with a net inflow of 251 million [3] - Guomai Technology (002093) with a net inflow of 241 million [3] - Zhongyuan Xiehe (600645) with a net inflow of 102 million [3]

Core Viewpoint - Ruiang Gene experienced a decline of 5.44% in stock price on November 21, with a trading volume of 32.91 million yuan. The financing data indicates a net buying of 2.18 million yuan on that day, while the total financing and securities balance reached 59.36 million yuan, reflecting a low financing balance compared to historical levels [1][2]. Group 1: Company Overview - Ruiang Gene Technology Co., Ltd. was established on February 17, 2012, and went public on May 17, 2021. The company specializes in the research, production, and sales of in vitro diagnostic products, including testing instruments and reagents, primarily focusing on blood diseases, solid tumors, and infectious diseases [2]. - The revenue composition of Ruiang Gene includes 84.23% from self-produced reagents, 6.86% from testing services, 6.63% from purchased reagents, 1.28% from research services, and 1.00% from other sources [2]. Group 2: Financial Performance - For the period from January to September 2025, Ruiang Gene reported an operating income of 139 million yuan, a year-on-year decrease of 26.64%. The net profit attributable to the parent company was -5.62 million yuan, reflecting a significant year-on-year decline of 198.14% [2]. - As of September 30, the number of shareholders for Ruiang Gene was 4,715, an increase of 0.62% from the previous period, while the average circulating shares per person decreased by 0.61% to 11,846 shares [2]. Group 3: Dividend Information - Ruiang Gene has distributed a total of 19.44 million yuan in dividends since its A-share listing [3].